Hudson Bay Capital Invests $2.81M in Repligen Corporation

Hedge fund takes stake in biotech firm focused on biopharmaceutical production technologies

Mar. 22, 2026 at 8:41am

Got story updates? Submit your updates here. ›

Hudson Bay Capital Management LP, a hedge fund, has purchased 21,003 shares of Repligen Corporation (NASDAQ:RGEN), a biotechnology company that develops and manufactures products for the biopharmaceutical industry. The investment, valued at approximately $2.81 million, was disclosed in a recent 13F filing with the SEC.

Why it matters

Repligen is a leading provider of critical technologies and consumables used in the production of biopharmaceuticals. Hudson Bay's investment signals confidence in Repligen's business model and growth prospects within the rapidly expanding biopharmaceutical manufacturing sector.

The details

According to the 13F filing, Hudson Bay Capital Management acquired the 21,003 shares of Repligen in the third quarter of the previous fiscal year. Repligen is a Massachusetts-based company that specializes in technologies supporting the development and production of biopharmaceuticals, including chromatography resins, filtration membranes, and single-use systems.

  • Hudson Bay Capital Management purchased the Repligen shares in the third quarter of the previous fiscal year.

The players

Hudson Bay Capital Management LP

A hedge fund that has invested $2.81 million in Repligen Corporation.

Repligen Corporation

A biotechnology company that develops and manufactures products for the biopharmaceutical industry, including chromatography resins, filtration membranes, and single-use systems.

Got photos? Submit your photos here. ›

The takeaway

Hudson Bay Capital's investment in Repligen underscores the growing importance of specialized technologies and consumables in the biopharmaceutical manufacturing sector, which continues to experience robust growth driven by the development of new biologics and increasing demand for existing therapies.